1-8 of 8
Michael Friedlander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Shannon L. Puhalla, Véronique Diéras, Banu K. Arun, Bella Kaufman, Hans Wildiers, Hyo S. Han, Jean-Pierre Ayoub, Vered Stearns, Yuan Yuan, Teresa Helsten, Bridget Riley-Gillis, Erin Murphy, Madan G. Kundu, Meijing Wu, David Maag, Christine K. Ratajczak, Cyril Y. Ramathal, Michael Friedlander
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 4983–4993.
https://doi.org/10.1158/1078-0432.CCR-21-0748
Published: 15 September 2021
View article titled, Relevance of Platinum-free Interval and <em>BRCA</em> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<em>BRCA</em> Advanced Breast Cancer (BROCADE3 Crossover)
Open the PDF for Relevance of Platinum-free Interval and <em>BRCA</em> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<em>BRCA</em> Advanced Breast Cancer (BROCADE3 Crossover) in another window
Includes: Supplementary data
Journal Articles

Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL

Anna Piskorz, David Robertson, Kevin K. Lin, James Morris, Elaina Mann, Amit Oza, Robert L. Coleman, David M. O'Malley, Michael Friedlander, Janiel M. Cragun, Ling Ma, Heidi Giordano, Iain A. McNeish, Elizabeth Swisher, James Wason, James D. Brenton
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): GMM-048.
https://doi.org/10.1158/1557-3265.OVCASYMP18-GMM-048
Published: 15 November 2019
View article titled, Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL
Journal Articles

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype

Masataka Takenaka, Martin Köbel, Dale W. Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara, Hiroyuki Takahashi, Takako Kiyokawa, Masahiro Ikegami, Hirokuni Takano, Seiji Isonishi, Kazuhiko Ochiai, Nadia Traficante, Sreeja Gadipally, Timothy Semple, Dane Vassiliadis, Kausyalya Amarasinghe, Jason Li, Gisela Mir Arnau, Aikou Okamoto, Michael Friedlander, David D. L. Bowtell
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3962–3973.
https://doi.org/10.1158/1078-0432.CCR-18-3691
Published: 01 July 2019
View article titled, Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype
Open the PDF for Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype in another window
Includes: Supplementary data
Journal Articles

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

Dale W. Garsed, Kathryn Alsop, Sian Fereday, Catherine Emmanuel, Catherine J. Kennedy, Dariush Etemadmoghadam, Bo Gao, Val Gebski, Valérie Garès, Elizabeth L. Christie, Maartje C.A. Wouters, Katy Milne, Joshy George, Ann-Marie Patch, Jason Li, Gisela Mir Arnau, Timothy Semple, Sreeja R. Gadipally, Yoke-Eng Chiew, Joy Hendley, Thomas Mikeska, Giada V. Zapparoli, Kaushalya Amarasinghe, Sean M. Grimmond, John V. Pearson, Nicola Waddell, Jillian Hung, Colin J.R. Stewart, Raghwa Sharma, Prue E. Allan, Peter F. Rambau, Orla McNally, Linda Mileshkin, Anne Hamilton, Sumitra Ananda, Marisa Grossi, Paul A. Cohen, Yee C. Leung, Robert M. Rome, Philip Beale, Penny Blomfield, Michael Friedlander, Alison Brand, Alexander Dobrovic, Martin Köbel, Paul Harnett, Brad H. Nelson, David D. L. Bowtell, Anna deFazio, Nadia Traficante, for the Australian Ovarian Cancer Study Group
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (3): 569–580.
https://doi.org/10.1158/1078-0432.CCR-17-1621
Published: 31 January 2018
View article titled, Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer
Open the PDF for Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL

Anna Piskorz, Kevin K. Lin, James Morris, Elaina Mann, Amit Oza, Robert L. Coleman, David M. O'Malley, Michael Friedlander, Janiel M. Cragun, Ling Ma, Heidi Giordano, Nitzan Rosenfeld, Mitch Raponi, Iain A. McNeish, Elizabeth Swisher, James D. Brenton
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): AP27.
https://doi.org/10.1158/1557-3265.OVCASYMP16-AP27
Published: 31 May 2017
View article titled, Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL
Journal Articles

Abstract A3: Mucinous ovarian tumors: Are they all the same?

Ian Campbell, Sally Hunter, Wakefield Mathew, Yoland Antill, Susie Bae, Sumitra Ananda, Monique Topp, Lara Lipton, Winston Liauw, Thomas Jobling, Alex Boussioutas, Michael Christie, Prue Allan, Michael Friedlander, Stephen Fox, Anna Defazio, David Bowtell, Jan Pyman, Study Australian Ovarian Cancer, Clare Scott, Kylie Gorringe
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A3.
https://doi.org/10.1158/1078-0432.OVCA13-A3
Published: 13 May 2014
View article titled, Abstract A3: Mucinous ovarian tumors: Are they all the same?
Journal Articles

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

Michael S. Anglesio, Joshy George, Hagen Kulbe, Michael Friedlander, Danny Rischin, Charlotte Lemech, Jeremy Power, Jermaine Coward, Prue A. Cowin, Colin M. House, Probir Chakravarty, Kylie L. Gorringe, Ian G. Campbell, Australian Ovarian Cancer Study Group, Aikou Okamoto, Michael J. Birrer, David G. Huntsman, Anna de Fazio, Steve E. Kalloger, Frances Balkwill, C. Blake Gilks, David D. Bowtell
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2538–2548.
https://doi.org/10.1158/1078-0432.CCR-10-3314
Published: 14 April 2011
View article titled, IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
Open the PDF for IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer in another window
Includes: Supplementary data
Journal Articles

Oxaliplatin and Axonal Na+ Channel Function In vivo

Arun V. Krishnan, David Goldstein, Michael Friedlander, Matthew C. Kiernan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4481–4484.
https://doi.org/10.1158/1078-0432.CCR-06-0694
Published: 09 August 2006
View article titled, Oxaliplatin and Axonal Na<sup>+</sup> Channel Function <em>In vivo</em>
Open the PDF for Oxaliplatin and Axonal Na<sup>+</sup> Channel Function <em>In vivo</em> in another window